Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections

Table 1 Demographic and clinical characteristics of 349 people living with human immunodeficiency virus and hepatitis C virus genotype 6 co-infections

Variables	Data
Age at DAA initiation, mean (SD), yr	48.9 (11.7)
Male sex, n (%)	288 (82.5)
Transmission route of HIV infection, n (%)
Men who have sex with men	63 (18.1)
Heterosexuals	5 (1.4)
People who inject drugs	281 (80.5)
CD4 counts ≥ 200 cells/mm3, n (%)	331 (94.8)
Plasma HIV viral loads < 50 copies/mL, n (%)	335 (96.0)
eGFR at baseline, mean (SD), mL/min/1.73m2	94.0 (20.5)
Receiving ART, n (%)	349 (100.0)
Switch of ART before DAA, n (%)	27 (7.7)
Backbone antiretroviral agent, n (%)
TAF-based	92 (26.4)
TDF-based	120 (34.4)
Non-TDF/TAF-based	137 (39.3)
The third antiretroviral agent
nNRTI	106 (30.4)
PI	14 (4.0)
InSTI, n/N (%)	233 (66.8)
RAL	10/233 (4.3)
EVG	92/233 (39.5)
DTG	131/233 (56.2)
Cirrhosis of the liver, n (%)	38 (10.9)
Hepatocellular carcinoma, n (%)	3 (0.9)
HCV treatment-experienced, n (%)	38 (10.9)
DAA, n	4
Interferon/ribavirin, n	35
HCV seroconversion1 within 1 yr, n (%)	18 (5.2)
Transmission route of HCV infection, n (%)
Sexual transmission	43 (12.3)
Injection drug use	279 (79.9)
Blood transfusion	1 (0.3)
Unknown	26 (7.4)
HCV RNA viral load, mean (SD), log10 IU/mL	6.2 (1.1)
Mixed HCV infection, n (%)	8 (2.3)
Positive HBsAg, n (%)	43 (12.3)
Undetectable HBV DNA load (< 20 IU/mL) before DAA initiation, n/N (%)	10/13 (76.9)
Undetectable HBV DNA load after completion of DAA therapies, n/N (%)	6/7 (85.7)
DAA agents, n (%)
GLE/PIB	181 (51.9)
SOF/LDV	145 (41.5)
SOF/VEL	22 (6.3)
SOV/DCV	1 (0.3)
Plasma HIV RNA < 50 copies/mL after DAA, n/N (%)	289/306 (94.4)

¹HCV seroconversion was defined as change of anti-HCV antibody from negativity to positivity. ART: Antiretroviral therapy; DAA: Direct-acting antiviral; DTG: Dolutegravir; EVG: Elvitegravir; GLE/PIB: Glecaprevir/pibrentasvir; HBsAg: Hepatitis B surface antigen; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; InSTI: Integrase strand transfer inhibitor; n: Patient number; N: Number of patients with data available; nNRTI: Non-nucleoside reverse-transcriptase inhibitor; PI: Protease inhibitor; RAL: Raltegravir; SD: Standard deviation; SOF/DCV: Sofosbuvir/daclatasvir; SOF/LDV: Sofosbuvir/ledipasvir; SOF/VEL: Sofosbuvir/velpatasvir; TAF: Tenofovir alafenamide; TDF: Tenofovir disoproxil fumarate.